Showing 1 - 10 of 18
Persistent link: https://www.econbiz.de/10009404302
Objective: Development of an aggregate quality index to evaluate hospital performance in cardiovascular events treatment. Methods: We applied a two-stage regression approach using an accelerated failure time model based on variance weights to estimate hospital quality over four cardiovascular...
Persistent link: https://www.econbiz.de/10015325463
The COVID-19 pandemic considerably impacted the lives of European citizens. This study aims to provide a nuanced picture of well-being patterns during the pandemic across Europe with a special focus on relevant socio-economic sub-groups. This observational study uses data from a repeated,...
Persistent link: https://www.econbiz.de/10015404261
This paper examines the behaviour of mental health care providers in response to marginal payment incentives induced by a discontinuous per diem reimbursement schedule with varying tariff rates over the length of stay. The analyses use administrative data on 12,627 cases treated in 82...
Persistent link: https://www.econbiz.de/10014503545
We use longitudinal patient-level data from a German sickness fund with 7.26 million insured in a Markov-simulation model to assess the cost-effectiveness of long-acting injectable risperidone (LAI-RIS) compared with long-acting injectable flupentixol (LAI-FLX) in the long-term management of...
Persistent link: https://www.econbiz.de/10010993904
Predicted costs for LA were 1,856 US$ lower than for OA while the postoperative complication rate did not differ significantly. Thus, LA is the treatment of choice from a provider’s perspective. </AbstractSection> Copyright Springer-Verlag 2012
Persistent link: https://www.econbiz.de/10010993925
Persistent link: https://www.econbiz.de/10008486763
Persistent link: https://www.econbiz.de/10009149810
In response to rapidly rising pharmaceutical costs, many countries have introduced health technology assessment (HTA) as a 'fourth hurdle'. We evaluated the causal effect of HTA based regulation on access to pharmaceuticals by using the introduction of Germany's HTA system (AMNOG) in 2011. We...
Persistent link: https://www.econbiz.de/10015325421
In response to rapidly rising pharmaceutical costs, many countries have introduced health technology assessment (HTA) as a 'fourth hurdle'. We evaluated the causal effect of HTA based regulation on access to pharmaceuticals by using the introduction of Germany's HTA system (AMNOG) in 2011. We...
Persistent link: https://www.econbiz.de/10015325474